Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities

Abstract

Cannabinoid pharmacology has been intensely studied because of cannabis' pervasive medicinal and non-medicinal uses as well as for the therapeutic potential of cannabinoid-based drugs for the treatment of pain, anxiety, substance abuse, obesity, cancer and neurodegenerative disorders. The identification of allosteric modulators of the cannabinoid receptor 1 (CB$_1$) has given a new direction to the development of cannabinoid-based therapeutics due to the many advantages offered by targeting allosteric site(s). Allosteric receptor modulators hold potential to develop subtype-specific and pathway-specific therapeutics. Here we briefly discuss the first-generation of allosteric modulators of CB$_1$ receptor, their structure-activity relationships, signaling pathways and the allosteric binding site(s) on the CB$_1$ receptor. This article is part of the Special Issue entitled "A New Dawn in Cannabinoid Neurobiology".